SCHEMBL5669188

SCHEMBL5669188

COc1ccc(-c2ccccc2)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccncc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR142 Q7Z601 1/20 0.47
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
MAPT P10636 2/20 0.46
LMNA P02545 1/20 0.46
EPHB4 P54760 6/20 0.45
TP53 P04637 1/20 0.45
KDR P35968 2/20 0.44
TEK Q02763 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
POLB P06746 1/20 0.43
ITGB1 P05556 1/20 0.43
ITGA4 P13612 1/20 0.43
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
HPGD P15428 1/20 0.42
HTR6 P50406 1/20 0.42
THRA P10827 1/20 0.42
THRB P10828 1/20 0.42
PTGER3 P43115 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5585843 0.87 EPHB4 (0.52) MEN1KMT2AMAPTLMNAEPHB4
SCHEMBL5593089 0.85 EPHB4 (0.54) MEN1KMT2AMAPTLMNAEPHB4
SCHEMBL5586132 0.84 MEN1 (0.57) MEN1KMT2AMAPTLMNAEPHB4
SCHEMBL5668989 0.84 KDM4E (0.43) MEN1KMT2AMAPTLMNAEPHB4
SCHEMBL5592628 0.84 ERBB4 (0.43) MEN1KMT2AMAPTLMNAEPHB4
SCHEMBL5592903 0.83 MAPT (0.47) MEN1KMT2AMAPTLMNAEPHB4
SCHEMBL5602071 0.83 HTR2C (0.54) MEN1KMT2AMAPTLMNAEPHB4
SCHEMBL5612270 0.82 MAPT (0.48) MEN1KMT2AMAPTLMNAEPHB4
SCHEMBL12028947 0.82 THRA (0.44) MEN1KMT2AMAPTLMNAEPHB4
SCHEMBL5611827 0.82 EPHB4 (0.45) MEN1KMT2AMAPTLMNAEPHB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1858879-B1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY GILEAD CONNECTICUT INC (US) 2012-06-06 EP claimed
EP-1858879-A1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY CGI Pharmaceuticals, Inc. (US) 2007-11-28 EP claimed
US-20060199846-A1 Certain substituted ureas as modulators of kinase activity GILEAD CONNECTICUT, INC. 2006-09-07 US claimed
WO-2006076593-A1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY CGI PHARMACEUTICALS, INC. (US) 2006-07-20 WO claimed
EP-1858879-B1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY GILEAD CONNECTICUT INC (US) 2012-06-06 EP disclosed
EP-2397478-A1 1,3-diaryl substituted ureas as modulators of kinase activity. CGI Pharmaceuticals, Inc. (US) 2011-12-21 EP disclosed
US-20060199846-A1 Certain substituted ureas as modulators of kinase activity GILEAD CONNECTICUT, INC. 2006-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199846-A1 Certain substituted ureas as modulators of kinase activity UCK2, CHUK, AXL GPR142 2514/4885MEN1 3417/4885KMT2A 3501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.